Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Relay's"


2 mentions found


Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock. Relay stock has slumped 40% in 2024. "We believe the 2H update will help show the superior efficacy/safety profile for Relay's PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib," Lawson said. Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer. That outcome, "all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2," the bank said.
Persons: Peter Lawson, Relay's, Lawson Organizations: Barclays, Therapeutics
That fee can be passed on to customers to save restaurants money. "The DoorDash self-delivery is a hack," Simmons, whose organization represents 550 local delivery operators in the US, said. And by deploying the self-delivery tactic with apps like Grubhub and DoorDash, restaurants can save even more money, Blum said. Colonel Delivery restaurants partners that use self-delivery can't pass on delivery fees to DashPass customers. But the "hack" is worth looking into if it can save restaurants from paying higher third-party delivery fees, he added.
Total: 2